Nonetheless, future investigations using normal hematopoietic cells (PBMCs or CD34+ progenitors) and primary CML patient samples are essential to validate whether the observed inverse expression pattern between miR-122-5p and CDC25A is conserved in the hematopoietic environment. The gene discussed is CDC25A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.